Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,640 GBX | -0.64% | -5.20% | +13.09% |
Jun. 06 | GSK Closes Up to $50 Million Purchase of US-based Elsie Biotechnologies | MT |
Jun. 06 | GSK: acquisition of US biotech Elsie | CF |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+13.09% | 85.94B | B | ||
+43.64% | 749B | C+ | ||
+39.42% | 605B | B | ||
-6.58% | 351B | C+ | ||
+19.72% | 328B | B- | ||
+8.78% | 292B | C+ | ||
+11.92% | 216B | B- | ||
-2.62% | 214B | A+ | ||
+0.03% | 167B | C+ | ||
+6.13% | 165B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- GSK Stock
- Ratings GSK plc